SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Pharmacy Practice
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Militello, M. A.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Role of Nesiritide in Decompensated Heart Failure

Michael A. Militello, PharmD, BCPS

Cleveland Clinic Foundation, Department of Pharmacy/HB3, 9500 Euclid Ave, Cleveland, OH 44195, militem{at}ccf.org

Nesiritide is a human brain type natriuretic peptide. The addition of nesiritide, a balanced venous and arterial dilator for the treatment of decompensated heart failure, is the first intravenous (IV) therapy developed in the past decade. Nesiritide binds to receptors in the kidneys, vasculature, and other organs to produce vasodilation and natriuresis. These effects act to reduce ventricular filling pressures and rapidly improve symptoms of heart failure. Nesiritide reduces pulmonary capillary wedge pressure and pulmonary artery pressure, improves the cardiac index, and has minimal effects on heart rate. The limiting side effect of nesiritide is dose-related hypotension. It should not be used in patients with suspected or measured low filling pressures or patients with baseline hypotension. Current literature supports the efficacy of nesiritide; however, there are very few outcome data demonstrating the superiority of nesiritide over conventional therapy. Because this vasodilator does not require hemodynamic monitoring for utilization, it may be an attractive agent for a defined group of patients with decompensated heart failure.

Key Words: nesiritide • heart failure • B-type natriuretic peptide • vasodilation

Journal of Pharmacy Practice, Vol. 15, No. 4, 326-333 (2002)
DOI: 10.1177/089719002129041313
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement